广济药业(000952) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥178,582,464.34, representing an increase of 11.43% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was -¥41,171,630.66, a significant decrease of 759.72% year-on-year[5] - The basic earnings per share for Q3 2023 was -¥0.1163, a decrease of 736.69% year-on-year[5] - In Q3 2023, the company reported a net profit loss of ¥71,794,280.01, compared to a net profit of ¥18,272,970.78 in Q3 2022, indicating a significant decline in performance[27] - The company's operating profit was reported at -¥73,418,280.12, a decrease from an operating profit of ¥18,222,605.45 in the same period last year[27] - Total revenue from sales of goods and services was ¥496,182,697.06, down from ¥599,915,308.54 in Q3 2022, reflecting a decline of approximately 17.2%[29] - The company's total comprehensive income for Q3 2023 was -¥71,788,088.01, compared to ¥18,261,637.36 in Q3 2022, highlighting a substantial drop in overall financial health[28] - The basic earnings per share (EPS) for Q3 2023 was reported at -0.1892, compared to an EPS of 0.0564 in the same quarter last year[28] Assets and Liabilities - The total assets as of September 30, 2023, amounted to ¥3,178,054,084.27, reflecting a growth of 28.72% from the end of the previous year[5] - The total liabilities increased, with long-term borrowings rising by 91.58% to ¥469,265,000.00 due to a special loan for the acquisition project[9] - The company's total liabilities as of September 30, 2023, amounted to CNY 1,694,963,351.71, compared to CNY 977,247,826.66 at the start of the year[24] Cash Flow - The cash flow from operating activities for the year-to-date was -¥128,965,768.15, a drastic decline of 21,443.75% compared to the same period last year[10] - The net cash flow from operating activities was -¥128,965,768.15, compared to -¥598,622.65 in the previous year, indicating a worsening cash flow situation[30] - Cash and cash equivalents at the end of the period stood at ¥543,423,723.82, an increase from ¥352,866,514.95 at the end of Q3 2022[30] Investments and Financing - The company’s investment activities generated a net cash outflow of -¥552,402,189.50, primarily due to payments for the acquisition project[10] - The company plans to borrow RMB 200 million from its controlling shareholder, Changjiang Industrial Investment Group, at an interest rate of 4.8%[16] - The company is engaging in a financing lease for production equipment, with a financing amount of RMB 140 million and a lease term of 3 years[17] - The company raised ¥52,000,000.00 from new investments and ¥593,800,000.00 from borrowings during the quarter, indicating ongoing financing activities to support operations[30] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,862[12] - The largest shareholder, Changjiang Industrial Investment Group, holds 24.75% of shares, totaling 87,592,065 shares[12] - The controlling shareholder's lock-up shares of 37,539,103 shares were released from restrictions on April 18, 2023[18] - The company has no known related party relationships among the top ten shareholders, except for the controlling shareholder[13] Subsidiaries and Joint Ventures - The company has established a joint venture with Jining Yanzhou District Huimin Urban Construction Investment Co., with a registered capital of RMB 520 million, where the company holds 90%[14] - The company established a wholly-owned subsidiary, Hubei Guanghua Pharmaceutical Co., Ltd., to serve as a chemical synthesis base as part of its "raw materials + formulations + health" development strategy[19] - Hubei Guangji Health Technology Co., Ltd. was set up to focus on the development of traditional Chinese medicine and health products, aligning with the company's strategic goals[19] Research and Development - The company incurred R&D expenses of ¥48,939,908.18, slightly down from ¥51,573,922.12 in Q3 2022, showing a focus on maintaining R&D investment despite financial losses[27] - Hubei Guangji Health Technology has launched five health products, including Coenzyme Q10 soft capsules and B vitamins, and is in the process of developing a functional liver-protecting beverage[20] Accounting and Corrections - The company corrected prior accounting errors affecting the consolidated financial statements for 2022 and 2021, with no impact on the profit and loss statement[18] - The company has completed the cancellation of its fundraising special account as the funds have been fully utilized[20]